Get the Stockscreener App
1.315
5.96%
-0.085
Moleculin Biotech Inc Stock (MBRX) Latest News
MGO Global, Moleculin Biotech, and Sacks Parente Golf Lead Penny Stock Surge - PUNE.NEWS
Moleculin Announces FDA Guidance for MIRACLE Trial Acceleration in Relapsed or Refractory AML - DocWire News
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech (NASDAQ:MBRX) Enters Into Warrant Exercise Inducement Agreement - Defense World
Moleculin Biotech Receives FDA Guidance for Phase 3 Trial on Annamycin-Cytarabine Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants -February 13, 2025 at 01:33 pm EST - Marketscreener.com
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Benzinga
Moleculin Biotech secures $5.8 million from warrant exercise - Investing.com
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Stock market news: Tantech Holdings declined by 97.05% while Moleculin Biotech surged by 590.48% during midday trading - Business Upturn
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - PR Newswire
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine - MSN
Moleculin (MBRX) Stock Rallies On Positive Regulatory Developments - Stocks Telegraph
Moleculin's Phase 3 AML trial gets FDA nod for size reduction - Investing.com
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
Stock market today: Tantech Holdings declined by 97.39% while Moleculin Biotech surged by 354.76% in early trading - Business Upturn
Moleculin Biotech Gets FDA Nod for Phase 3 Trial - TipRanks
Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks
Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia - Marketscreener.com
FDA Accelerates Game-Changing Leukemia Treatment Trial: Moleculin's Non-Cardiotoxic Solution Shows Promise - StockTitan
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy? - AOL
Moleculin Biotech (NASDAQ:MBRX) Receives First Country Regulatory Approval in Europe for Phase 3 Clinical Trial Protocol for Annamycin Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com India
Moleculin Announces First European Approval for Phase 3 AML Trial By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters into Waiver and Consent Agreement with Investor - Defense World
The Significance of Moving Averages in Moleculin Biotech Inc Inc. (MBRX) Price Performance - The InvestChronicle
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
MBRX’s price-to-free cash flow ratio: What it means for investors - US Post News
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - The Malaysian Reserve
Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial - Marketscreener.com
Moleculin Biotech Gains European Approval for Phase 3 Trial - TipRanks
Moleculin Biotech receives first approval in Europe for AML trial recruiting - TipRanks
Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial - Marketscreener.com
Moleculin Biotech (MBRX) First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - StreetInsider.com
Major Milestone: Moleculin (MBRX) Secures Critical European Green Light for Groundbreaking AML Treatment Trial - StockTitan
Moleculin Biotech reaches agreement to amend investor warrants By Investing.com - Investing.com Australia
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
Moleculin Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Closing Bell Recap: Moleculin Biotech Inc (MBRX) Ends at 0.84, Reflecting a -15.27 Downturn - The Dwinnex
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, - openPR
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor Segment: 8-K Filing Reveals - Defense World
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor “What this Means” segment – 8-K Filing News - Defense World
Comparing Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Shares Updates on MIRACLE Trial - TipRanks
Amendment: Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Launches MIRACLE Study for AML - TipRanks
0.07%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):